全文获取类型
收费全文 | 3009篇 |
免费 | 169篇 |
国内免费 | 100篇 |
出版年
2023年 | 6篇 |
2022年 | 32篇 |
2021年 | 61篇 |
2020年 | 12篇 |
2018年 | 36篇 |
2017年 | 28篇 |
2016年 | 100篇 |
2015年 | 231篇 |
2014年 | 236篇 |
2013年 | 253篇 |
2012年 | 300篇 |
2011年 | 275篇 |
2010年 | 172篇 |
2009年 | 111篇 |
2008年 | 114篇 |
2007年 | 99篇 |
2006年 | 63篇 |
2005年 | 143篇 |
2004年 | 145篇 |
2003年 | 97篇 |
2002年 | 79篇 |
2001年 | 71篇 |
2000年 | 43篇 |
1999年 | 26篇 |
1998年 | 26篇 |
1997年 | 26篇 |
1996年 | 28篇 |
1995年 | 10篇 |
1994年 | 12篇 |
1993年 | 47篇 |
1992年 | 36篇 |
1991年 | 18篇 |
1990年 | 30篇 |
1989年 | 21篇 |
1988年 | 28篇 |
1987年 | 16篇 |
1986年 | 26篇 |
1985年 | 19篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1978年 | 6篇 |
1974年 | 6篇 |
1973年 | 5篇 |
1972年 | 7篇 |
1968年 | 5篇 |
1962年 | 5篇 |
1957年 | 10篇 |
1955年 | 7篇 |
1951年 | 5篇 |
1923年 | 5篇 |
排序方式: 共有3278条查询结果,搜索用时 15 毫秒
61.
A Skogl?f I Nilsson S Gustafsson J Deinum P O G?the 《Biochimica et biophysica acta》1990,1041(1):22-30
The angiotensin I-converting enzyme (peptidyl-dipeptide hydrolase, EC 3.4.15.1) inhibitor, ramiprilat (2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-Ala]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid), is shown to exist in tow conformational isomers, cis and trans, which interconvert around the amide bond. The two conformers were separated by reversed-phase high-performance liquid chromatography. The conformers were identified by nuclear Overhauser effect measurements. From line shape analysis the isomerization rate constants were determined to be kcis----trans = 15 s-1 and ktrans----cis = 5 s-1 at 368 K in [2H]phosphate buffer (p2H 7.5). By enzyme kinetic studies using 3-(2-furylacryloyl)-L-Phe-Gly-Gly as substrate, the trans conformer was found to be the most potent enzyme inhibitor, whereas the cis conformer had a very low inhibitory effect. A new inhibition mechanism is presented for this type of slow, tight-binding inhibitors that contain an amide bond. This mechanism involves an equilibrium between the two conformers and the enzyme-bound inhibitor complex. 相似文献
62.
Michael A. Baker Robert N. Taub Walter H. Carter the Toronto Leukemia Study Group 《Cancer immunology, immunotherapy : CII》1982,13(2):85-88
Summary Forty-eight patients with acute myeloblastic leukemia in remission were treated with immunotherapy in addition to remission-maintenance chemotherapy. The first 16 patients were treated with weekly BCG and a leukemia cell vaccine (group 1). The next 32 patients were randomly allocated to receive BCG and a leukemia cell vaccine given once monthly (group 2) or BCG given monthly with no leukemia cell vaccine (group 3). There was no significant difference in remission duration or survival between the randomly allocated groups (2 and 3).Comparisons with group 1 are limited by the non-random allocation to this group, but selection bias was unlikely and clinical features were similar in the three patient groups. No significant difference in remission duration or survival was seen amongst the three groups studied. There was no advantage in the addition of leukemia cell vaccine (groups 1 and 2) to BCG alone (group 3) and no advantage to weekly (group 1) versus monthly immunotherapy (groups 2 and 3). Only 7 of the 48 patients achieved a second remission, and 4 of these were short-term partial remissions.The following are contributing members of the Toronto Leukemia Study Group: Doctor's Hospital, Harvey Silver MD; Humber Memorial Hospital, Alan Seidenfeld MD; Mississauga Hospital, Michael King MD; Mount Sinai Hospital, Dominic Amato MD; Northwestern Hospital, Wilhelm Kwant MD; Oshawa General Hospital, Hak Chiu MD; St Michael's Hospital, Bernadette Garvey MD, Kenneth Butler MD; St Joseph's Hospital, H. James Watt MD, Murray Davidson MD; Toronto General Hospital, Gerald Scott MD, William Francombe MD, Kenneth Shumak MD; John Crookston MD, PhD; Toronto Western Hospital, James G. Watt MD, David Sutton MD; Michael Baker MD; Domenic Pantalony MD; Wellesley Hospital, Dale Dotten MD; Women's College Hospital, George Kutas MD; York Finch Hospital, Sam Berger MD 相似文献
63.
Marco Gobbi Michele Baccarani Donatella Ruggero Sante Tura the Italian Cooperative Study Group on Chronic Myeloid Leukemia 《Cancer immunology, immunotherapy : CII》1979,6(1):59-62
Summary Serum immunoglobulin concentration and skin reactivity to at least three recall antigens were determined in 210 patients with chronic myeloid leukemia (CML). Immunoglobulin concentration was normal in the great majority of the patients. Skin tests were negative in 50 of 210 cases (24%). No relationship could be demonstrated between skin reactivity, age, time since diagnosis, WBC, lymphocyte count, and splenectomy. Prior antileukemic therapy was a major factor in determining the response to skin tests.S. Tura (Chairman) and M. Baccarani (Secretary), Cattedra di Ematologia dell'Università e Servizio di Ematologia dell'Ospedale S. Orsola, Bologna; G. de Sandre, G. Perona, G. Cetto, G. Pizzolo, Istituto di Patologia Medica e Cattedra di Ematologia dell'Università, Verona; P. Rambotti, B. Falini, Clinica Medica dell'Università, Perugia; T. Chisesi, G. Capnist, Divisione di Ematologia, Ospedale Civile, Vicenza; A. Cajozzo, P. Citarella, Cattedra di Ematologia dell'Università, Palermo; G. Broccia, Sezione di Ematologia, Ospedale Armando Businco, Cagliari; V. Liso, G. Troccoli, Clinica Medica II dell'Università, Bari; L. Bruzzese, G. Nappi, A. Abbadessa, Clinica Medica (I Facoltà) dell'Università, Napoli; A. Porcellini, C. Delfini, Divisione di Ematologia, Ospedali Riuniti, Pesaro; E. Cacciola, R. Giustolisi, R. Musso, V. Raimondi, Cattedra di Ematologia dell'Università, Catania; G. Torlontano, L. Geraci, Cattedra di Ematologia dell'Università, Chieti, e Divisione di Ematologia, Ospedale Civile, Pescara; F. Mandelli, G. Mariani, B. Monarca, N. Petti, Cattedra di Ematologia dell'Università, Roma; R. di Guglielmo, A. Miliani, Clinica Medica dell'Università, Firenze; C. Bernasconi, M. Lazzarino, G. Castelli, Divisione di Ematologia, Ospedale S. Matteo, Pavia; A. Alberti, S. Magro, Servizio di Ematologia, Ospedale Generale Regionale, Catanzaro; A. Neri, P. Iacopino, Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria; R. Delsignore, M. C. Baroni, Istituto di Patologia Medica dell'Universita, Parma; E. Bajetta, S. Monfardini, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano; S. Tognella, Istituto Scientifico di Medicina Interna, Cattedra di Clinica Medica 2R, Università, Genova. 相似文献
64.
基于节水灌溉技术原理与作物感知缺水的根源信号理论而提出的根系分区交替灌溉,是交替对作物部分根区进行正常的灌溉,其余根区受到适度水分胁迫的灌溉方式。应用同位素示踪技术追溯分根区交替供水条件下土壤-作物系统水分运转途径并揭示其节水调质机理是一个重要的研究方向。本文对根系分区交替灌溉的节水调质效应、节水机理、稳定性氢氧同位素在植物水分运移中的应用以及稳定性碳同位素在植物水分利用效率中的应用研究进展及应用前景作了简要介绍,并对将来需要重点研究的方向作了展望。以期为充分挖掘作物生理节水潜力,大幅度提高作物水分利用效率和实现节水、丰产、优质、高效的综合目标提供有效的调控途径。 相似文献
65.
肠道病毒71型作为引起儿童群体常见传染性手足口病(HFMD)的主要病原,具有导致少量感染个体出现脑炎等神经系统病变以及相关心肺功能衰竭的病理学特性.因此其预防性疫苗的研发具有重要的公共卫生意义.在前期工作的基础上,一种EV71灭活病毒疫苗(人二倍体细胞)在本研究中基于恒河猴婴猴模型进行了相应的免疫保护性分析.以160EU剂量对2~3月龄婴猴进行0,4周免疫后,动物在第4周接受了剂量为10。~CCID50的病毒经呼吸道的攻击.对病毒攻击后动物在14天内的临床症状、血液生物学、器官病原学分布以及病理学检测的动态观察表明,经疫苗免疫的动物未出现对照动物所具有的特征性临床表现,其血液生物学及病理学检测均无异常.同时,器官病原学分布亦呈阴性.结合动物中和抗体的明确增长及对照动物的综合表现分析,本文的工作证实了该EV71灭活病毒疫苗(人二倍体细胞)在恒河猴婴猴体内的免疫保护性. 相似文献
66.
以黄河三角洲潮间带盐地碱蓬种子生成的幼苗为材料,研究了NaCl胁迫对盐地碱蓬生长与根系边缘细胞的影响。盐地碱蓬的第一个边缘细胞几乎与根尖同步产生,当根长达到13mm时,边缘细胞数目达到最大值。NaCl胁迫抑制边缘细胞的活性,但低浓度的NaCl处理增加边缘细胞的数目。低浓度NaCl处理时果胶甲基酯酶(PME)的活性比对照有明显增加,超氧化物歧化酶(SOD)活性随着NaCl浓度的增加呈现先上升后下降的趋势,低浓度NaCl可以增加盐地碱蓬根内过氧化氢酶(CAT)的活性,NaCl处理时间和处理浓度都对过氧化物酶(POD)活性的影响不明显。这些结果表明,盐地碱蓬至少部分通过增加调控活性氧(ROS)水平增加PME活性及根系边缘细胞数目来抵抗NaCl胁迫。 相似文献
67.
将金莓菌的芽孢接种到不同的接种培养基中,24小时后再接种到同一的酦酵培养基上,发现金霉素的产量有显著不同。一个好的接种培养基比一个坏的接种培养基所生的菌体在酦酵过程中产生的金霉素可以大出7至8倍。接种培养基的 pH 值对于以后菌体在酦酵培养基中金霉素的生产也有显著的影响。接种培养基并不显著地影响菌体在酦酵培养基上的生长,但已显然变更了它的代谢作用。由不同接种培养基中萌生的菌体,在同一酦酵培养基中醣的利用率不同,氧化的能力不同,有机酸的形成和堆积也不同,它们对于一些金属元素的反应也不一样。这个研究证明了金霉菌的初期的培养环境,对于以后菌体的发育和金霉素的生产有极大的影响。同时亦指出了金霉菌的发育在不同时期需要不同的环境,有着不同的代谢类型。去掌握这个生物规律——环境条件和发育的过程,是正确的研究方向,是提高抗生素产量的必要途径。 相似文献
68.
鸡IL-18成熟蛋白基因的克隆及分子进化分析 总被引:1,自引:0,他引:1
根据已发表的鸡白介素18(IL-18)基因序列设计合成引物,以植物凝集素(PHA)和脂多糖(LPS)激活的AA肉鸡脾细胞mRNA为模板,通过RT-PCR扩增出编码鸡IL-18成熟蛋白的eDNA。将该eDNA克隆于pUCm-T载体,并对其进行测序,结果表明所克隆的核苷酸片段包含了全部成熟蛋白编码基因,成熟蛋白编码区507个核苷酸,编码169个氧基酸。把该基因编码的鸡成熟IL-18蛋白氨基酸序列与已公布的禽及哺乳动物IL-8成熟蛋白基因氧基酸序列进行比较,其同源性分别在96.5%~100%和20.1%~26.6%之间,分子系统进化树分析表明鸡IL-18与哺乳动物IL-18有共同的祖先,亲源关系较近,但在免疫系统选择性压力下,形成独特的种族特异性。鸡IL-18基因的克隆为体外表达鸡IL-18蛋白及作为免疫佐剂应用于预防接种的研究奠定了基础。 相似文献
69.
继对芝麻矮化坏死病源研究之后,又对普遍发生的芝麻黄花叶病害分离物(YMo—I)进行了系统鉴定。该分离物普遍存在于各芝麻主产区,普通年份发病率为1~5%。YMo—I侵染芝麻引起叶片褪绿及黄绿相间花叶。摩擦接种能够侵染4科12种(品种)植物。局部侵染苋色藜、昆诺藜;系统侵染大豆、花生、望江南、克氏烟等。该病毒能够由桃蚜、花生蚜、大豆蚜以非持久性方式进行传播。ELISA检测其病株种子带毒率为0.5%,但尚未发现种生病苗。病毒在组织汁液中存活期3天;钝化温度55~60℃,稀释限点4×10~(-3)。提纯病毒为弯曲线状粒体,大小约为13×730nm。并有极易凝聚的趋势。病组织中诱导大量典型PVY第一亚组的风轮形和卷筒状细胞质内含体和少数多边形结晶核内含体。血清学上该病毒与花生条纹病毒(PStV)、西瓜花叶病毒—2(MMV—2)密切相关,与花生斑驳病毒、大豆花叶病毒弱相关;与芜菁花叶病毒不相关。但它不侵染WMV—2的寄主—黄瓜,并且该病害田间的发生流行与芝麻、花生的间作方式以及PStV在花生田间的流行密切相关。根据上述结果,YMo—I分离株被鉴定为花生条纹病毒的一芝麻分离株。 相似文献
70.
Kleerebezem R Beckers J Hulshoff Pol LW Lettinga G 《Biotechnology and bioengineering》2005,91(2):169-179
The feasibility was studied of anaerobic treatment of wastewater generated during purified terephthalic acid (PTA) production in two-stage upflow anaerobic sludge blanket (UASB) reactor system. The artificial influent of the system contained the main organic substrates of PTA-wastewater: acetate, benzoate, and terephthalate. Three parallel operated reactors were used for the second stage, and seeded with a suspended terephthalate degrading culture, with and without additional methanogenic granular sludge (two different types). The first stage UASB-reactor was seeded with methanogenic granular sludge. Reactors were operated at 37 degrees C and pH 7. During the first 300 days of operation a clear distinction between the biomass grown in both reactor stages was obtained. In the first stage, acetate and benzoate were degraded at a volumetric loading rate of 40 g-COD/L . day at a COD-removal efficiency of 95% within the first 25 days of operation. No degradation of terephthalate was obtained in the first stage during the first 300 days of operation despite operation of the reactor at a decreased volumetric loading rate with acetate and benzoate of 9 g-COD/L . day from day 150. Batch incubation of biomass from the reactor with terephthalate showed that the lag-phase prior to terephthalate degradation remained largely unchanged, indicating that no net growth of terephthalate degrading biomass occurred in the first stage reactor. From day 300, however, terephthalate degradation was observed in the first stage, and the biomass in this reactor could successfully be enriched with terephthalate degrading biomass, resulting in terephthalate removal capacities of 15 g-COD/L . day. Even though no single reason could be identified why (suddenly) terephthalate degradation was obtained after such a long period of operation, it is suggested that the solid retention time as well the prevailing reactor concentrations acetate and benzoate may have played an important role. From day 1 of operation, terephthalate was degraded in the second stage. In presence of methanogenic granular biomass, high terephthalate removal capacities were obtained in these reactors (15 g-COD/L . day) after approximately 125 days of operation. From the results obtained it is concluded that terephthalate degradation is the bottleneck during anaerobic treatment of PTA-wastewater. Pre-removal of acetate and benzoate in staged bioreactor reduces the lag-phase prior to terephthalate degradation in latter stages, and enables high rate treatment of PTA-wastewater. 相似文献